Home›Trial›NCT04716231
NCT04716231Phase 3ACTIVE NOT RECRUITING

Atacicept in Subjects With IgA Nephropathy

Study Summary

A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)

Conditions
IgA NephropathyBerger Disease
Interventions / Drugs
AtaciceptPlacebo to match Atacicept
View on ClinicalTrials.gov ↗
Sponsor
VERA
Vera Therapeutics
Nephrology
C63/100
Study Details
Enrollment376 participants
Primary Completion—
Lead SponsorVera Therapeutics, Inc.
Data Retrieved2026-04-11 04:30:54.036488+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 376 participants
Sponsor Catalyst Profile

Vera Therapeutics (VERA) is the sponsoring company for this trial. BiotechSign currently grades this company C (63/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

VERA Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.